Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his co-authord, published in Blood Advances, adding:
“I’m delighted to have contributed to this European multicentre study on acquired pure red cell aplasia (PRCA), one of the rare diseases I most enjoy managing.
Acquired PRCA is an underrecognized entity, even among hematologists, as reflected by the median time from presentation to treatment of 2 months (range: 1–204 months) observed in our study.
PRCA should be promptly suspected in any patient with severe anemia and a low reticulocyte count. In our study, earlier initiation of cyclosporine A was associated with a better response.
Our study also shows that PRCA is characterized by markedly elevated erythropoietin levels (median: 908 mIU/mL; range: 29–3000 mIU/mL), likely related to reduced degradation by erythroblasts.
These findings argue against a significant role for erythropoietin analogues in the management of PRCA.
At diagnosis, most patients had elevated ferritin levels and transferrin saturation, reflecting rapid iron accumulation and reduced iron utilization.
Reticulocytes are crucial not only for diagnosis but also as an early marker of response, as highlighted in the paper –look at the reticulocytes!
Thanks to Bruno Fattizzo and Francesco Versino for their initiative, leadership, and excellent work.”
Title: Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Authors: Francesco Versino,Marc Michel,Jennifer Vidler, Salvador Payán-Pernía,Roochi Trikha,Shreyans A Gandhi,Sukanya Gogoi,Manujasr, Wimalachandra,Omar Racchi,Maria Teresa Lupo-Stanghellini,Sabrina Giammarco,Maria Arguello Marina,Mara Memoli,Andreas Glenthøj,Gabriele Merati, Yamuna Wasanthi Wickramasinghe,Aparna Chitharanjan,Mylene Hemmer,Mariasanta Napolitano,Margarita Jimenez-Jambrina,Filippo Brioschi, Antonio Palma-Vallelano,Tomas Jose Gonzalez-Lopez,Cristina Clissa,Marta Bortolotti,Giacinto Luca Pedone,Giorgio Alberto Croci,Francesco Passamonti, Wilma Barcellini, Austin G Kulasekararaj, Bruno Fattizzo
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date